Aerovate Therapeutics, Inc. (AVTE)
NASDAQ: AVTE · Real-Time Price · USD
2.530
0.00 (0.00%)
At close: Mar 28, 2025, 4:00 PM
2.507
-0.023 (-0.90%)
Pre-market: Mar 31, 2025, 4:01 AM EDT
Aerovate Therapeutics Employees
Aerovate Therapeutics had 30 employees as of December 31, 2024. The number of employees decreased by 21 or -41.18% compared to the previous year.
Employees
30
Change (1Y)
-21
Growth (1Y)
-41.18%
Revenue / Employee
n/a
Profits / Employee
-$2,320,933
Market Cap
73.33M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 30 | -21 | -41.18% |
Dec 31, 2023 | 51 | 8 | 18.60% |
Dec 31, 2022 | 43 | 27 | 168.75% |
Dec 31, 2021 | 16 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AVTE News
- 9 days ago - AEROVATE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Aerovate Therapeutics, Inc. - AVTE - Business Wire
- 5 months ago - SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AVTE and PFIE on Behalf of Shareholders - PRNewsWire
- 9 months ago - Aerovate Therapeutics to Explore Strategic Alternatives - GlobeNewsWire
- 10 months ago - Investigation Into Aerovate Therapeutics, Inc. (AVTE) Announced byHolzer & Holzer, LLC - GlobeNewsWire
- 10 months ago - Aerovate Therapeutics Investors: Investigation on behalf of investors; the Portnoy Law Firm - GlobeNewsWire
- 10 months ago - Aerovate Therapeutics Announces 24-Week Topline Results from the Phase 2b Portion of IMPAHCT Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension - GlobeNewsWire
- 10 months ago - Aerovate: Imatinib Delivery Change Leads To Targeting Of Massive PAH Market - Seeking Alpha
- 11 months ago - Aerovate Therapeutics Presents Baseline Data from the Phase 2b Portion of the IMPAHCT Trial at the American Thoracic Society 2024 International Conference - GlobeNewsWire